10-Q: AptarGroup Reports Q1 2025 Results: Sales Dip Slightly Amid Currency Headwinds, Pharma Segment Drives Growth

AptarGroup's Q1 2025 net sales decreased by 3% year-over-year, primarily due to unfavorable foreign currency exchange rates, though the Pharma segment showed strong growth.

Summary

• AptarGroup's net sales for Q1 2025 were $887.3 million, a 3% decrease compared to $915.4 million in Q1 2024.
• Foreign currency exchange rates negatively impacted results by 3%.
• Core sales were flat compared to the same period last year.
• Operating income increased slightly to $113.4 million from $112.1 million.
• Net income attributable to AptarGroup was $78.8 million, down from $83.1 million in the prior year.
• The effective tax rate increased to 25.8% from 20.5% due to a temporary surtax in France and lower tax benefits from share-based compensation.
• Aptar Pharma's net sales increased by 1% to $409.5 million, with core sales up 3%.
• Aptar Beauty's net sales decreased by 7% to $305.7 million, with core sales down 3%.
• Aptar Closures' net sales decreased by 5% to $172.1 million, with core sales down 2%.
• The company expects Q2 2025 earnings per share to be in the range of $1.56 to $1.64, excluding restructuring expenses, changes in the fair value of equity investments, and acquisition costs.
• Total 2025 estimated cash outlays for capital expenditures net of government grant proceeds are expected to be approximately $280 million to $300 million.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While sales and net income are down, the Pharma segment shows strength, and the company is actively managing costs. The outlook for Q2 is positive, but there are several economic and geopolitical risks.

Positives

• Aptar Pharma segment showed strong core sales growth of 3%, driven by prescription and active material science solutions.
• Adjusted EBITDA margin improved in Aptar Pharma to 34.8% from 32.5% in the prior year.
• Aptar Closures' Adjusted EBITDA margin improved from 15.0% to 15.8%.
• The company is actively managing costs and implementing cost improvement initiatives.
• The company refinanced debt in 2024, extending the maturity date of the revolving credit facility to July 2029.
• The company declared a quarterly cash dividend of $0.45 per share.

Negatives

• Overall net sales decreased by 3% due to unfavorable foreign currency exchange rates.
• Aptar Beauty segment experienced a 3% decrease in core sales due to softer European demand.
• Aptar Closures segment experienced a 2% decrease in core sales.
• Net income attributable to AptarGroup decreased from $83.1 million to $78.8 million.
• SG&A expenses increased by approximately $2.5 million.
• The effective tax rate increased to 25.8% from 20.5%.

Risks

• Economic conditions worldwide, including inflationary and potential deflationary conditions.
• Geopolitical conflicts, including the invasion of Ukraine.
• Tariffs and other restrictions on foreign imports.
• Cybersecurity threats.
• Availability of raw materials and components.
• Lower demand and asset utilization due to economic recession.
• Fluctuations in foreign currency exchange rates and effective tax rate.
• Financial conditions of customers and suppliers.
• Loss of key accounts.
• Changes in capital availability or cost, including rising interest rates.
• Product liability claims.

Future Outlook

The company expects Q2 2025 earnings per share to be in the range of $1.56 to $1.64, excluding restructuring expenses, changes in the fair value of equity investments, and acquisition costs, based on an effective tax rate range of 19% to 21%.

Management Comments

• Strong volume growth, especially for our products in our prescription and closures segments, more than compensated for lower tooling and beauty volumes, net of any price adjustments.

Industry Context

AptarGroup operates in the dispensing systems and drug delivery market, which is influenced by factors such as pharmaceutical industry trends, consumer spending on beauty and personal care products, and demand for sustainable packaging solutions. The company's performance is affected by competition, technological advancements, and regulatory changes.

Comparison to Industry Standards

• AptarGroup's performance can be compared to companies like Berry Global, Amcor, and West Pharmaceutical Services, which operate in similar packaging and dispensing solutions markets.
• AptarGroup's Adjusted EBITDA margins in its Pharma segment (34.8%) are generally strong compared to overall packaging industry averages, reflecting the higher value-added nature of its products.
• The company's focus on cost management and restructuring initiatives aligns with industry trends to improve profitability and efficiency.

Legal Proceedings

• The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature.
• We have received claims worth approximately $10 million to $11 million in principal, and $21 million to $22 million for interest and penalties.

Related Party Transactions

• For the three months ended March 31, 2025 and March 31, 2024, we had purchases of $3.0 million and $2.3 million, respectively, from BTY.
• As of March 31, 2025 and December 31, 2024, approximately $1.5 million and $2.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets.

Stakeholder Impact

• Shareholders will receive a quarterly dividend of $0.45 per share.
• Employees are affected by restructuring initiatives and changes in compensation costs.
• Customers may be impacted by changes in product demand and pricing adjustments.
• Suppliers are affected by changes in payment terms and supply chain management.

Next Steps

• The company expects to make a $10.0 million contribution to its domestic defined benefit plans by the end of the second quarter of 2025.
• The company will continue to evaluate liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.

Key Dates

Keywords

AptarGroup, Financial Results, Q1 2025, Net Sales, Earnings, Pharma, Beauty, Closures, Adjusted EBITDA, Core Sales, Currency Impact, Share Repurchase, Dividends